Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan.

Saita, Mizue; Yan, Yan; Ito, Kanami; Sasano, Hiroshi; Seyama, Kuniaki; Naito, Toshio

Saita, Mizue; Yan, Yan; Ito, Kanami; Sasano, Hiroshi; Seyama, Kuniaki; Naito, Toshio.

Afiliación

Saita M; Department of General Medicine, Juntendo University Faculty of Medicine, Japan; Department of Safety and Health Promotion, Juntendo University, Japan.
Yan Y; Department of Palliative Medicine, Juntendo University Graduate School of Medicine, Japan.
Ito K; Department of Safety and Health Promotion, Juntendo University, Japan.
Sasano H; Department of Pharmacy, Juntendo University Hospital, Japan.
Seyama K; Department of Safety and Health Promotion, Juntendo University, Japan; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan.
Naito T; Department of General Medicine, Juntendo University Faculty of Medicine, Japan; Department of Safety and Health Promotion, Juntendo University, Japan. Electronic address: naito@juntendo.ac.jp.

J Infect Chemother ; 28(1): 116-119, 2022 Jan.

Article en En | MEDLINE | ID: mdl-34580011

Asunto(s)

Vacunas contra la COVID-19; COVID-19; Vacuna BNT162; Femenino; Personal de Salud; Humanos; Japón; ARN Mensajero/genética; SARS-CoV-2

Palabras clave

Adverse reaction; BNT162b2; COVID-19 vaccine; Japan; Reactogenicity

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Límite: Female / Humans País/Región como asunto: Asia Idioma: En Revista: J Infect Chemother Asunto de la revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google